Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus PYOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus PYOCIDIN.
CHLORAMPHENICOL SODIUM SUCCINATE vs PYOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S ribosomal subunit, inhibiting peptidyl transferase activity and blocking protein synthesis in bacteria.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Intravenous, 50 mg/kg/day divided every 6 hours; maximum 4 g/day.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3.5 hours in adults with normal renal and hepatic function. In neonates (first 2 weeks of life), half-life is prolonged to 10-24 hours due to immature hepatic conjugation. In patients with severe hepatic impairment, half-life may exceed 12 hours, necessitating dose adjustment.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 80-90% of the dose is excreted renally as unchanged drug and as the inactive chloramphenicol base (formed by hydrolysis in the liver and kidneys). Biliary excretion accounts for about 5-10%, with some enterohepatic circulation. Fecal excretion is negligible (<2%).
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Category D/X
Category C
Antibiotic
Antibiotic